Emerging diuretics for the  treatment of heart failure.
Heart failure continues to be a major global concern. Despite greater understanding of the 'maladaptive' mechanisms that contribute to its development and progression, morbidity and mortality from heart failure remain high. Existing treatment modalities have been hampered by the development of electrolyte abnormalities, diuretic resistance and the cardiorenal syndrome. This review focuses on the pharmacological properties and clinical data of therapeutic agents under investigation that target vasopressin and adenosine receptors for the treatment of patients with heart failure.
Sedghi
Yabiz
Y
Department of Cardiology, Ochsner Clinic Foundation, New Orleans, Louisiana 70121, USA.
Gaddam
Krishna K
KK
Ventura
Hector O
HO
D000818:Animals; D065092:Antidiuretic Hormone Receptor Antagonists; D002986:Clinical Trials as Topic; D018450:Disease Progression; D004232:Diuretics / Q000494:pharmacology / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D004351:Drug Resistance; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology / Q000503:physiopathology; D058915:Purinergic P1 Receptor Antagonists; D013577:Syndrome; D014883:Water-Electrolyte Imbalance / Q000209:etiology
D065092:Antidiuretic Hormone Receptor Antagonists; D004232:Diuretics; D058915:Purinergic P1 Receptor Antagonists